Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Legislators And Bond Holders Knocking At Valeant’s Door

This article was originally published in The Pink Sheet Daily

Executive Summary

The troubled drug maker received a notice of default from bondholders, while CEO Michael Pearson agreed to be deposed by the Senate’s Special Committee on Aging April 18.

You may also be interested in...



Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs

Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”

At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath

Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.

Astellas Plots US Portfolio Expansion

US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel